β受体阻滞剂与肺癌患者生存：荟萃分析。
Beta-blocker and survival in patients with lung cancer: A meta-analysis.
机构信息
Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Department of Endocrinology and Metabolism, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
出版信息
PLoS One. 2021 Feb 16;16(2):e0245773. doi: 10.1371/journal.pone.0245773. eCollection 2021.
BACKGROUND
Beta-blocker (BB) is suggested to have anticancer efficacy. However, the potential influence of BB use on overall survival (OS) in patients with lung cancer remains undetermined. We aimed to evaluate the above relationship in an updated meta-analysis.
METHODS
Observational studies comparing OS between users and non-users of BB with lung cancer were identified by search of PubMed, Embase, and Cochrane's Library. A random-effect model was used to pool the results.
RESULTS
Ten retrospective cohort studies with 30870 patients were included. Overall, BB use was not associated with significantly improved OS in lung cancer (hazard ratio [HR] = 1.02, 95% confidence interval [CI]: 0.98 to 1.06, p = 0.33) with moderate heterogeneity (I2 = 29%). Stratified analyses showed similar results in patients with non-small cell lung cancer and small cell lung cancer, in studies with BB use before and after the diagnosis of lung cancer, and in studies with or without adjustment of smoking. Use of BB was associated with improved OS in patients with stage III lung cancer (HR = 0.91, 95% CI: 0.85 to 0.98, p = 0.02) and in patients that did not receive surgery resection (HR = 0.78, 95% CI: 0.64 to 0.96, p = 0.02), while use of non-selective BB was associated with worse OS (HR = 1.14, 95% CI: 1.01 to 1.28, p = 0.03).
CONCLUSIONS
This meta-analysis of retrospective cohort studies does not support a significant association between BB use and improved OS in lung cancer.
背景
β受体阻滞剂（BB）具有抗癌作用。然而，BB 使用对肺癌患者总生存（OS）的潜在影响仍不确定。我们旨在通过更新的荟萃分析来评估上述关系。
方法
通过检索 PubMed、Embase 和 Cochrane 图书馆，确定了比较 BB 使用与肺癌患者 OS 的观察性研究。使用随机效应模型汇总结果。
结果
纳入了 10 项回顾性队列研究，共 30870 例患者。总体而言，BB 使用与肺癌患者的 OS 改善无关（风险比[HR] = 1.02，95%置信区间[CI]：0.98 至 1.06，p = 0.33），异质性中等（I2 = 29%）。分层分析显示，在非小细胞肺癌和小细胞肺癌患者、BB 使用在肺癌诊断前后的研究、以及有或无吸烟调整的研究中，结果相似。BB 使用与 III 期肺癌患者的 OS 改善相关（HR = 0.91，95%CI：0.85 至 0.98，p = 0.02）和未接受手术切除的患者（HR = 0.78，95%CI：0.64 至 0.96，p = 0.02），而使用非选择性 BB 与较差的 OS 相关（HR = 1.14，95%CI：1.01 至 1.28，p = 0.03）。
结论
本荟萃分析回顾性队列研究不支持 BB 使用与肺癌患者 OS 改善之间存在显著关联。
Zotero 插件